-+ 0.00%
-+ 0.00%
-+ 0.00%

Dongcheng Pharmaceutical (002675.SZ): Application for marketing of the API bemipheparin sodium was accepted

Zhitongcaijing·08/06/2026 12:49:18
Listen to the news

Zhitong Finance App News, Dongcheng Pharmaceutical (002675.SZ) issued an announcement. Recently, the company received the “Notice of Acceptance” approved and issued by the State Drug Administration regarding the marketing application for the active ingredient bemipheparin sodium. Bemipheparin sodium is a low molecular weight heparin. Its formulation is bemiferin sodium injection, which is suitable for preventing blood clotting in extracorporeal circulation during hemodialysis and preventing thromboembolic diseases in patients with general surgery and orthopedic surgery.